Skip to main content
Quest Diagnostics

Genetic Findings in a Cohort of Over 1800 Patients Tested With a Combined Cardiomyopathy and Arrhythmia Panel

ACMG Annual Clinical Genetics Meeting, 2024

American College of Medical Genetics and Genomics

Toronto, Canada, March 12-16, 2024

Poster presentation: Genetic Findings in a Cohort of Over 1800 Patients Tested With a Combined Cardiomyopathy and Arrhythmia Panel

Authors: Hathaway J, Huusko J, Cicerchia M, Ahonen S, Tommiska J, Gall K,  Liaquat K, Djupsjöbacka J, Muona M, Saarinen I, Seppälä E, Kangas-Kontio T, Koskinen L, Salmenperä P, Myllykangas S, Koskenvuo J

Specialty: Genetics, Cardiovascular disease, Cardiology, Endocrinology

Related content

Publication
GRINL1A Complex Transcription Unit Containing GCOM1, MYZAP, and POLR2M Genes Associates with Fully Penetrant Recessive Dilated Cardiomyopathy
Publication
Rare Variants in Genes Associated With Cardiomyopathy Are Not Common
Conference Presentation
A retrospective review of mitochondrial genome NGS analysis in 7000 rare disease patients

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.